Lupin Limited, the global pharmaceutical company, announced today the launch of Meloxicam Capsules, 5 mg, and 10 mg, having received an approval from the United States Food and Drug Administration.

Meloxicam Capsules, 5 mg and 10 mg, is the generic equivalent of Vivlodex Capsules, 5 mg and 10 mg, of Zyla Life Sciences US, Inc., and indicated for the management of osteoarthritis (OA) pain.

Meloxicam Capsules (RLD: Vivlodex) had an annual sales of approximately USD 11 million in the U.S. (IQVIA MAT October 2020).

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across the Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the 3rd largest pharmaceutical company in the U.S. by prescriptions and 5th in India by global revenues. The Company invests 9.6 % of its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research centres, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.